hema.to, a Munich, Germany-based digital medtech company, raised €3.6M in funding.
The round was led by LUMO Labs and followed by Bayern Kapital and investors from their previous round.
The company intends to use the funds to refine product-market-fit in their first segment of blood cancer diagnostics, including additional European certification, and for clinical studies, expansion into diagnosis of broader immune disorders, and scaling commercial deployment.
Founded in Munich in 2021 by Dr. Karsten Miermans (CEO), Felix Kunzweiler (CTO), Dr. Franz Elsner, and later joined by Dr. Aleksandra Mezydlo, Hema.to automates complex blood data analysis through AI-powered cytometry, reducing lab analysis time from ~20 minutes to 1 minute, eliminating human subjectivity in detecting leukaemia and lymphoma, and eradicating 90% of false negatives for secondary pathologies.
The company’s AI pulls data from a database of over 600,000 files from over 20 centers. With their CE-marked AI models for clinical-grade performance and their new end-to-end solution in the process of a new certification, Hema.to is already helping labs and hospitals across Europe diagnose blood cancers.
The company is headquartered in Munich and has 22 full-time employees across Germany, Portugal, Spain, Poland and Belgium.
FinSMEs
06/03/2025